EQS-News: Formycon AG
/ Key word(s): Regulatory Approval
Press Release // December 07, 2023
Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® Munich, Amsterdam, Zug, Toronto – Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has granted the “Notice of Compliance” (NOC) for Ranopto®1 (Ranibizumab), a biosimilar to Lucentis®2, for the treatment of several serious retinal diseases in Canada. Ranopto® is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual impairment due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO). FYB201/Ranopto® was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics. Mid 2021, Teva Pharmaceutical Industries Ltd. (“Teva”) entered into a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe and selected other countries. Commercial launch by Teva Canada Ltd. is expected to start in the first quarter of 2024. AMD is caused by excessive growth of blood vessels in the retina. Ranibizumab inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of these blood vessels in the retina. In developed countries AMD is the most common cause of severe visual impairment or blindness. The risk of being affected increases with age. In Canada, approximately 2.5 million people are affected by AMD with nearly 180,000 experiencing vision loss [i]. “After successful launches in the U.S., Europe and countries of the MENA region, we are very pleased that – together with our partner Teva – we are now able to provide a highly effective and affordable treatment option to patients in Canada with severe retinal diseases. With the second highest per capita sales and third highest per capita consumption in the OECD, anti-VEGF therapies in Canada have been a significant burden on public drug plans in the past. With our biosimilar, we can contribute to more competition and cost efficiency in this important therapeutic area", says Dr. Stefan Glombitza, CEO of Formycon AG. “The approval in Canada underlines the excellent work we have done together with our partners in the development of FYB201/Ranopto®. It brings us a big step closer to our goal of improving therapy access for people with nAMD and other prevalent eye diseases worldwide, and thereby contributing to a better quality of life for millions of people affected", says Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. “Teva Canada is very pleased along with our partners to launch Ranopto®. This marks an important milestone for our growing biosimilar portfolio and a new treatment option for Canadian patients with severe retinal disease as well as healthcare professionals”, says Michael Sine, General Manager Teva Canada. ------- 1 Ranopto® is a registered trademark of Bioeq AG.
About Formycon: About Bioeq: About Polpharma Biologics: About Teva: About Biosimilars: Contact: Disclaimer:
[i] Larissa Moniz, Chad Andrews, Jennifer Pereira: „Canadian patient experience with age-related macular degeneration“ in ARVO Annual Meeting Abstract, June 2022 https://iovs.arvojournals.org/article.aspx?articleid=2781783
07.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Formycon AG |
Fraunhoferstraße 15 | |
82152 Planegg-Martinsried | |
Germany | |
Phone: | 089 864667 100 |
Fax: | 089 864667 110 |
Internet: | www.formycon.com |
ISIN: | DE000A1EWVY8 |
WKN: | A1EWVY |
Indices: | Scale 30 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1791015 |
End of News | EQS News Service |
|
1791015 07.12.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.